JP2024539193A5 - - Google Patents

Info

Publication number
JP2024539193A5
JP2024539193A5 JP2024523783A JP2024523783A JP2024539193A5 JP 2024539193 A5 JP2024539193 A5 JP 2024539193A5 JP 2024523783 A JP2024523783 A JP 2024523783A JP 2024523783 A JP2024523783 A JP 2024523783A JP 2024539193 A5 JP2024539193 A5 JP 2024539193A5
Authority
JP
Japan
Prior art keywords
rnai agent
nucleotide
agent according
modified
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523783A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078498 external-priority patent/WO2023070082A2/en
Publication of JP2024539193A publication Critical patent/JP2024539193A/ja
Publication of JP2024539193A5 publication Critical patent/JP2024539193A5/ja
Pending legal-status Critical Current

Links

JP2024523783A 2021-10-22 2022-10-21 マトリックスメタロプロテイナーゼ7(MMP7)の発現を抑制するためのRNAi剤、その組成物、及び使用の方法 Pending JP2024539193A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163270849P 2021-10-22 2021-10-22
US63/270,849 2021-10-22
US202263308289P 2022-02-09 2022-02-09
US63/308,289 2022-02-09
US202263345654P 2022-05-25 2022-05-25
US63/345,654 2022-05-25
PCT/US2022/078498 WO2023070082A2 (en) 2021-10-22 2022-10-21 Rnai agents for inhibiting expression of matrix metalloproteinase 7(mmp7), compositions thereof, and methods of use

Publications (2)

Publication Number Publication Date
JP2024539193A JP2024539193A (ja) 2024-10-28
JP2024539193A5 true JP2024539193A5 (cg-RX-API-DMAC7.html) 2025-10-28

Family

ID=86059695

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523783A Pending JP2024539193A (ja) 2021-10-22 2022-10-21 マトリックスメタロプロテイナーゼ7(MMP7)の発現を抑制するためのRNAi剤、その組成物、及び使用の方法

Country Status (13)

Country Link
US (1) US20230265437A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419689A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024539193A (cg-RX-API-DMAC7.html)
KR (1) KR20240099296A (cg-RX-API-DMAC7.html)
AU (1) AU2022368927A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235224A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001175A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024005110A2 (cg-RX-API-DMAC7.html)
IL (1) IL312239A (cg-RX-API-DMAC7.html)
MX (1) MX2024004912A (cg-RX-API-DMAC7.html)
PE (1) PE20241185A1 (cg-RX-API-DMAC7.html)
TW (1) TW202334416A (cg-RX-API-DMAC7.html)
WO (1) WO2023070082A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2025014897A (es) * 2023-06-13 2026-02-03 Tuojie Biotech Shanghai Co Ltd Arnip dirigido a mmp7, conjugado de arnip y su uso medico
CN121693569A (zh) 2023-07-28 2026-03-17 长春金赛药业有限责任公司 siRNA及其组合物
WO2025152967A1 (zh) * 2024-01-15 2025-07-24 武汉人福创新药物研发中心有限公司 靶向αvβ6的化合物及其用途
WO2025228156A1 (zh) * 2024-04-30 2025-11-06 北京炫景瑞医药科技有限公司 肾靶向的双链寡核苷酸缀合物及其用途
WO2026130467A1 (zh) * 2024-12-18 2026-06-25 上海拓界生物医药科技有限公司 一种RNAi剂及其医药用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20050118625A1 (en) * 2003-10-02 2005-06-02 Mounts William M. Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
WO2006092795A2 (en) * 2005-03-01 2006-09-08 Qbi Enterprises Ltd. Oligoribonucleotides and methods of use thereof for treatment of ocular scarring and other fibrotic conditions
SG11202002967SA (en) * 2017-11-01 2020-05-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
CA3082591A1 (en) * 2017-11-15 2019-05-23 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (nash) and advanced liver fibrosis
TW202130809A (zh) * 2019-10-29 2021-08-16 美商愛羅海德製藥公司 用於抑制β-ENaC表現之RNAi藥劑、其組合物及使用方法
WO2022056286A1 (en) * 2020-09-11 2022-03-17 Arrowhead Pharmaceuticals, Inc. Integrin targeting ligands and uses thereof

Similar Documents

Publication Publication Date Title
JP2025185070A5 (cg-RX-API-DMAC7.html)
JP2024516096A5 (cg-RX-API-DMAC7.html)
JP2020526192A5 (cg-RX-API-DMAC7.html)
JP2025128190A5 (cg-RX-API-DMAC7.html)
JP2023519246A5 (cg-RX-API-DMAC7.html)
JP7697889B2 (ja) アルファ-1アンチトリプシン欠乏症(aatd)の治療法
TW201803989A (zh) 拮抗b型肝炎病毒之組成物和藥劑及彼等之用途
JP2016523863A5 (cg-RX-API-DMAC7.html)
CN1247473A (zh) 治疗与呼吸失调和肺部炎症相关的疾病和症状的药剂和方法
JP2023536999A (ja) B型肝炎患者のオリゴヌクレオチド処置
CN107073114A (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
ES2301659T3 (es) Metodos para aumentar la eficacia in vivo de oligonucleotidos e inhibir la inflamacion en mamiferos.
JP2024515880A5 (cg-RX-API-DMAC7.html)
JP2024520522A5 (cg-RX-API-DMAC7.html)
JP2015532100A (ja) アンフィレギュリンに特異的な二重鎖オリゴrna、そのような二重鎖オリゴrnaを含む二重鎖オリゴrnaの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物
JP2023547274A (ja) マイクロrna-29の化合物、組成物、および治療法における使用
JP2023541170A (ja) Z-aatタンパク質のレベルを低下させる方法
CN105126112A (zh) 卵磷脂化超氧化物歧化酶作为有效成分在制备慢性阻塞性肺疾病改善剂中的应用
US20240309383A1 (en) Small interfering rna targeting hbv and uses thereof
Wang et al. Mucosal and transdermal delivery strategies for mRNA: Transforming the clinical applications
JP7514563B2 (ja) オルガノイドおよび抗炎症剤を含む炎症性腸疾患の予防または治療用薬学組成物
CN118019545A (zh) 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用
JP2024026903A (ja) siRNA及び医薬組成物並びに予防及び/又は治療剤
AU2013226216B2 (en) Method of treating chronic obstructive pulmonary disease
US20260103712A1 (en) Anti-fibrotic microrna composition